Department of Medicine, Massachusetts General Hospital, Boston, MA;
Clin Chem. 2014 Jan;60(1):35-43. doi: 10.1373/clinchem.2013.202531. Epub 2013 Nov 19.
Sex-based differences exist in the circulating concentrations of certain novel and established biomarkers in patients with acute coronary syndromes (ACS) and heart failure (HF). However, to date, few studies have compared the diagnostic and prognostic utility of these markers in men vs women.
This mini-review contains a discussion of the published reports of studies that have explored whether differences in biomarker concentrations exist between men and women with ACS or HF. It also examines those studies that have compared the utility of biomarkers for diagnosis or risk stratification in women vs men. Because biomarkers are often used to make therapeutic and triage decisions in patient care, the potential clinical implications for any observed differences in biomarker reference limits for men and women is discussed.
Although the concentration distributions may differ between men and women for certain biomarkers in clinical use, the clinical implications of these observations remain unclear. Because elements of the pathophysiology of ACS and HF may differ between the sexes, further research is needed to better evaluate the diagnostic and prognostic utility of biomarkers in men vs women.
在患有急性冠状动脉综合征（ACS）和心力衰竭（HF）的患者中，某些新型和已建立的生物标志物的循环浓度存在性别差异。然而，迄今为止，很少有研究比较这些标志物在男性和女性中的诊断和预后价值。
本迷你综述讨论了已发表的研究报告，这些报告探讨了 ACS 或 HF 患者中生物标志物浓度是否存在性别差异。它还检查了那些比较女性和男性生物标志物用于诊断或风险分层的效用的研究。由于生物标志物通常用于在患者护理中做出治疗和分诊决策，因此讨论了观察到的男性和女性生物标志物参考值差异的潜在临床意义。
尽管某些临床使用的生物标志物在男性和女性中的浓度分布可能存在差异，但这些观察结果的临床意义尚不清楚。由于 ACS 和 HF 的病理生理学要素在性别之间可能存在差异，因此需要进一步研究以更好地评估生物标志物在男性和女性中的诊断和预后价值。
